Marie Wencel

Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial

Jordi Díaz‐Manera, Priya S. Kishnani, Hani Kushlaf et al. · The Lancet Neurology · 2021 · 169 citations · Full text

Late-onset Pompe Disease, Autoimmune Disease, Clinical Infectious Disease +3

Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial

Benedikt Schoser, Mark Roberts, Barry J. Byrne et al. · The Lancet Neurology · 2021 · 124 citations

Clinical Trials, Cipaglucosidase Alfa, Pharmacotherapy +2

A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome

Virginia Kimonis, Abhilasha Surampalli, Marie Wencel et al. · PLoS ONE · 2019 · 45 citations · Full text

Alteration of Microbial Communities Colonizing Leaf Litter in a Temperate Woodland Stream by Growth of Trees under Conditions of Elevated Atmospheric CO ₂

John J. Kelly, Amit Bansal, Jonathan D. Winkelman et al. · Applied and Environmental Microbiology · 2010 · 29 citations · Full text

Chronic Mild Hypoxia Ameliorates Chronic Inflammatory Activity in Myelin Oligodendrocyte Glycoprotein (MOG) Peptide Induced Experimental Autoimmune Encephalomyelitis (EAE)

Paula Dore‐Duffy, Marie Wencel, Vladimir Katyshev et al. · Advances in experimental medicine and biology · 2011 · 24 citations

Inflammation, Autoimmune Disease, Medicine +10